Celebrating 25 years of the Swiss Biotech Association

Tuesday, April 25, 2023 @ 7:00 am

Some major achievements of Swiss biotech innovation…

1998 Monoclonal antibodies Trastuzumab
Herceptin, Roche, breast cancer
1998 Interferon beta-1a
Rebif, Serono, multiple sclerosis
2001 Bosentan
Tracleer, Actelion, pulmonary arterial hypertension (PAH)
2003 Kinase inhibitors Imatinib
Gleevec, Novartis, cancer
2013 CRISPR-Cas9 gene editing
CRISPR Therapeutics using technology to treat genetic diseases
2013 Humanized anti-CD20 monoclonal antibody Obinutuzumab
Gazyva, Glycart/Roche, chronic lymphocytic leukaemia
2017 CAR-T cell therapy Tisagenlecleucel
Kymriah, Novartis, leukaemia
2019 Humanized single chain antibody anti-VEGF Brolucizumab
Beovu, Esbatech/Novartis, wet-AMD
2019 Gene therapy Onasemnogene abeparvovec-xioi
Zolgensma, Novartis, paediatric spinal muscular atrophy (SMA)
2021 Aducanumab
Aduhelm, Neuroimmune/Biogen, Alzheimer’s disease
2023 DDM Genomics and Multimodal platform
SOPHiA GENETICS hits milestone of One Million Genomic Profiles analyzed by the SOPHiA DDM™ platform

Most of these highlights were achieved in international collaboration and benefit patients around the world. They do not represent a comprehensive list but rather a selection that emphasizes the diversity of modalities that have been developed over time and the broad range of medical needs they help to address.

You May Also Be Interested In

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Nouscom: Patient enrollment of study for metastatic colorectal cancer completed

Primary efficacy endpoint readout expected in mid-2025 Phase 1b studies in dMMR/MSI GI tumors showed that NOUS-209 with pembrolizumab was well-tolerated, generating potent and broad immune responses and durable tumor shrinkage NOUS-209 is being evaluated in multiple clinical studies targeting MSI cancers, from early-stage cancer interception through to metastatic disease
November 19, 2024

InSphero awarded major EU grant for diversity in 3D in vitro testing

InSphero, the global leader in scalable and reliable 3D in vitro cell culture solutions for drug discovery, takes a leading role in the recently awarded Chips JU European UNLOOC Project to advance its technology platform and address diversity in drug efficacy and safety testing.
November 18, 2024

Ymmunobio honored with 3rd place at the Prix Galien USA Awards

Ymmunobio is proud to announce its recent recognition at the prestigious Prix Galien USA Awards, where the company achieved a 3rd-place honor. The Prix Galien Award acknowledges Ymmunobio’s dedication to advancing science and healthcare.
November 15, 2024

Pharvaris: 3rd quarter 2024 financial results and business updates

Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at recent medical congresses Intend to engage in clinical development of deucrictibant for the treatment of acquired angioedema due to C1-INH deficiency (AAE-C1INH) Initiation of CHAPTER-3 global pivotal Phase 3 clinical study of deucrictibant for the
November 13, 2024

Aurealis Therapeutics: CHF 8M for chronic wounds studies and oncology program

Funds will be used to complete Phase 2 RCTs with AUP-16 for Chronic Wounds, and accelerate the development of AUP-55 for ovarian, peritoneal and bladder cancer.
November 13, 2024